CDNA vs CRL: fair value comparison
CareDx, Inc. and Charles River Laboratories International, Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CDNA currently sits closer to the top of our ranking by discount to fair value. CDNA carries the stronger quality grade.
| CDNA | CRL | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $64.00 | $301.79 |
| 12-month range | $14.28–$69.85 | $149.93–$310.77 |
| Rank by discount to fair value | #94 of 108 Healthcare | #108 of 108 Healthcare |
| Quality grade | A | F |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CDNA fair value analysis · CRL fair value analysis